Discontinuation of RAS Inhibitors in Advanced CKD — Has Equipoise Occurred?
- 1 December 2022
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 387 (22), 2083-2084
- https://doi.org/10.1056/nejme2214315
Abstract
Blockade of the renin–angiotensin system (RAS) is renoprotective beyond the effect of lowering blood pressure, especially in patients with mild-to-moderate chronic kidney disease (CKD).1,2 However, such renoprotection is far more effective when patients with CKD have proteinuria.1,2 As nephrologists, we struggle about whether to continue prescribing RAS inhibitors to patients with advanced (stage 4 or 5) CKD, given the perceived risks. We hope that stopping such treatment may lead to an increase (however modest) in the estimated glomerular filtration rate (eGFR), and we worry about possible drug-related hyperkalemia and other adverse events if RAS inhibition is continued. Although recent retrospective . . .This publication has 9 references indexed in Scilit:
- Renin–Angiotensin System Inhibition in Advanced Chronic Kidney DiseaseThe New England Journal of Medicine, 2022
- Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?Hypertension Research, 2022
- Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysisHypertension Research, 2022
- Stopping kidney protection in the elderly following acute kidney injury: think mortalityClinical Kidney Journal, 2022
- Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunctionJournal of Human Hypertension, 2021
- Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide StudyJournal of the American Society of Nephrology, 2020
- When should we start and stop ACEi/ARB in paediatric chronic kidney disease?Pediatric Nephrology, 2020
- Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trialsHypertension Research, 2019
- Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies ReportAmerican Journal of Kidney Diseases, 2018